Archives 2018

August 14, 2018

FDA Grants Orphan Drug Designation to Onspira Therapeutics’ Investigational Interleukin-1 Receptor Antagonist for the Treatment of Bronchiolitis Obliterans

March 19, 2018

Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB); Finalizes Novel, Once Daily Formulation; and Receives U.S. Patent Covering OAB

Please reload


640 Lee Road, Ste 110

Wayne, PA 19087

T +1 484.318.2988

F +1 484.324.7949

Nexeption Logo